Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 May 2006, Vol. 107, No. 9, pp. 3492-3494.
Prepublished online as a Blood First Edition Paper on January 12, 2006; DOI 10.1182/blood-2005-11-4541.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-11-4541v1
107/9/3492    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyakoshi, S.
Right arrow Articles by Oshimi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyakoshi, S.
Right arrow Articles by Oshimi, K.
Related Collections
Right arrow Neoplasia
Right arrow Brief Reports
Right arrowRelated Letter in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS
Brief report

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

Shigesaburo Miyakoshi, Masahiro Kami, Koichiro Yuji, Tomoko Matsumura, Masaaki Takatoku, Makoto Sasaki, Hiroto Narimatsu, Takeshi Fujii, Masateru Kawabata, Shuichi Taniguchi, Keiya Ozawa, and Kazuo Oshimi

From the Departments of Hematology, Pathology, and Respiratory Medicine, Toranomon Hospital, Tokyo, Japan; Division of Exploratory Research, the Institute of Medical Science, the University of Tokyo, Japan; Division of Hematology, Department of Medicine, Jichi Medical School, Tochigi, Japan; and the Division of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its frequent adverse effects are manageable, including gastrointestinal symptoms, peripheral neuropathy, and thrombocytopenia. Severe lung toxicity has not previously been reported. Between June 2004 and September 2005, 13 Japanese patients with multiple myeloma were treated with bortezomib in Toranomon Hospital, Juntendo University School of Medicine, and Jichi Medical School. Four of them developed severe pulmonary complications, and 2 died of respiratory failure without progression of underlying disease. To our knowledge, this is the first report on life-threatening pulmonary adverse effects after bortezomib therapy. Previous clinical studies on bortezomib, mostly in the United States and Europe, have shown low incidences of pulmonary adverse effects. Our study suggests that bortezomib can cause serious lung injury, and that its incidence might vary among different ethnicities. Clinicians need to be alert to the possibility.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Letter in Blood Online:

Severe pulmonary complication after bortezomib treatment for multiple myeloma
James E. Boyer, Reema B. Batra, Joao L. Ascensao, and Geraldine P. Schechter
Blood 2006 108: 1113. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C. Kane, R. Dagher, A. Farrell, C.-W. Ko, R. Sridhara, R. Justice, and R. Pazdur
Bortezomib for the Treatment of Mantle Cell Lymphoma
Clin. Cancer Res., September 15, 2007; 13(18): 5291 - 5294.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Zappasodi, R. Dore, C. Castagnola, C. Astori, M. Varettoni, S. Mangiacavalli, M. Lazzarino, and A. Corso
Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma
J. Clin. Oncol., August 1, 2007; 25(22): 3380 - 3381.
[Full Text] [PDF]

Home page
 ChestHome page
A. Thornburg, R. Abonour, P. Smith, K. Knox, and H. L. Twigg III
Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide
Chest, May 1, 2007; 131(5): 1572 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Boyer, R. B. Batra, J. L. Ascensao, and G. P. Schechter
Severe pulmonary complication after bortezomib treatment for multiple myeloma
Blood, August 1, 2006; 108(3): 1113 - 1113.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020